July 1st – 4th, 2020
ESMO World Congress on Gastrointestinal Cancer, 2020 Virtual
[Abstract P-80] A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)
29th May – 2nd June, 2020
American Association of Clinical Oncology (ASCO)
[Abstract TPS4666] Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)
Abstract #4617: ctDNA is prognostic and potentially predictive of eryaspase efficacy in patients with advanced pancreatic adenocarcinoma
December 10th – 14th, 2019
The San Antonio Breast Cancer Symposium
TRYbeCA-2: A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone As First-Line Treatment in Patients with Metastatic or Locally Recurrent Triple-Negative Breast Cancer (NCT03674242)
October 3rd – 4th, 2019
CAPACITES DE LA PLATEFORME THERAPEUTIQUE ERYCAPS®
Profil protéomique de globules rouges soumis à un procédé d’encapsulation par dialyse hypotonique
October 2nd – 4th, 2019
DRUG-LOADED ERYTHROCYTES AS A NEW THERAPEUTIC OPTION IN ONCOLOGY
September 27th – October 1st, 2019
TRYbeCA-2: A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone As First-Line Treatment in Patients with Metastatic or Locally Recurrent Triple-Negative Breast Cancer (NCT03674242)
September 6th – 9th, 2019
AACR pancreatic meeting, Boston
TRYbeCA-1: A Randomized, Phase 3 Study of Eryaspase in CombinaBon with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in PaBents with PancreaBc Adenocarcinoma (NCT03665441)
July 4th, 2019
ESMO World Congress on Gastrointestinal Cancer 2019
Abstract P-098: Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)
April 1st, 2019
AACR – American Association for Cancer Research
Erymethionase (methionine-γ-lyase encapsulated into red blood cells)
potentiates anti-PD1 therapy in TNBC-like syngeneic mouse model
March 11, 2019
ERCS European Red Cell Research Society 22nd Meeting
Comprehensive proteomic profiling of erythrocytes following hypotonic dialysis-based drug encapsulation process
January 17-19, 2019
Gastrointestinal Cancers Symposium (ASCO-GI)
Abstract TPS471: Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).
June 14-17, 2018
European Hematology Association (EHA) Congress
Preclinical Demonstration of Intracellular Activity of Asparaginase Encapsulated in Red Blood Cells Both in the Absence and in the Presence of Neutralizing Anti-Asparaginase Antibodies
Date/Time: Friday, June 15, 2018 / 5:30 p.m. – 7:00 p.m. (CEST)
A Phase 2b of Eryaspase in Combination with Low-Dose Cytarabine as First-Line Therapy in Elderly Patients with Acute Myeloid Leukemia (ENFORCE – NCT01810705)
Date/Time: Saturday, June 16, 2018 / 5:30 p.m. – 7:00 p.m. (CEST)
Venous Thromboembolism in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with Eryaspase (L-Asparaginase Encapsulated in Red Blood Cells)
June 1-5, 2018
American Society of Cancer Oncology (ASCO)
Pharmacodynamic Characterization of eryaspase (L-asparaginase Encapsulated in Red Blood Cells) in Combination with Chemotherapy in a Phase 2/3 Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517).
Date/Time: June 4, 2018 / 8:00 a.m. – 11:30 a.m
April 14-18, 2018
American Association for Cancer Research (AACR)
A Phase 1 Study Of Eryaspase (L-Asparaginase Encapsulated In Red Blood Cells) In Combination With Induction And Consolidation Chemotherapy For Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (NCT01910428)
Date/Time: April 15th, 2018
Enzymatic combination investigation in cancer therapy
Date/Time: April 18th, 2018
September 8-12th, 2017
European Society for Medical Oncology (ESMO)
A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)
Date/Time: September 8-11th,2017
September 5-8th, 2017
13th International Congress of Inborn Errors of Metabolism (ICIEM)
Eryminase, Arginine Deiminase-Encapsulated in Red Blood Cells Effectively Lower Blood Arginine Levels in a Mouse Model of Inducible Hyperargininemia
Date/Time: September 6th, 2017/ 5:30-8:00PM BRT
Erymethionase, Methioninase Entrapped in Red Blood Cells: an innovative treatment approach for classical homocystinuria
Date/Time: September 6th, 2017/ 5:30-8:00PM BRT
April 1-5, 2017
American Association for Cancer Research (AACR) Annual Meeting
Use of methionine gamma-lyase-loaded erythrocytes to induce effective methionine depletion of cancer therapy
Date/Time: April 3, 2017/1:00-5:00 PM EDT
January 19-21, 2017
2017 Gastrointestinal Cancers Symposium (ASCO GI)
Methionine gamma-lyase-encapsulated into red blood cells (ERY-MET) shows profound antitumor activity in gastric carcinoma